191 related articles for article (PubMed ID: 37945904)
21. Switching of chromatin-remodelling complexes for oestrogen receptor-alpha.
Okada M; Takezawa S; Mezaki Y; Yamaoka I; Takada I; Kitagawa H; Kato S
EMBO Rep; 2008 Jun; 9(6):563-8. PubMed ID: 18451880
[TBL] [Abstract][Full Text] [Related]
22. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
23. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
24. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
Pavlovic M; Arnal-Estapé A; Rojo F; Bellmunt A; Tarragona M; Guiu M; Planet E; Garcia-Albéniz X; Morales M; Urosevic J; Gawrzak S; Rovira A; Prat A; Nonell L; Lluch A; Jean-Mairet J; Coleman R; Albanell J; Gomis RR
J Natl Cancer Inst; 2015 Dec; 107(12):djv256. PubMed ID: 26376684
[TBL] [Abstract][Full Text] [Related]
25. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
26. PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.
Magnani L; Ballantyne EB; Zhang X; Lupien M
PLoS Genet; 2011 Nov; 7(11):e1002368. PubMed ID: 22125492
[TBL] [Abstract][Full Text] [Related]
27. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
28. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity.
Nair SS; Nair BC; Cortez V; Chakravarty D; Metzger E; Schüle R; Brann DW; Tekmal RR; Vadlamudi RK
EMBO Rep; 2010 Jun; 11(6):438-44. PubMed ID: 20448663
[TBL] [Abstract][Full Text] [Related]
29. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.
Wortham NC; Ahamed E; Nicol SM; Thomas RS; Periyasamy M; Jiang J; Ochocka AM; Shousha S; Huson L; Bray SE; Coombes RC; Ali S; Fuller-Pace FV
Oncogene; 2009 Nov; 28(46):4053-64. PubMed ID: 19718048
[TBL] [Abstract][Full Text] [Related]
30. UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor.
Xie G; Liu X; Zhang Y; Li W; Liu S; Chen Z; Xu B; Yang J; He L; Zhang Z; Jin T; Yi X; Sun L; Shang Y; Liang J
Oncogene; 2017 Sep; 36(39):5497-5511. PubMed ID: 28534508
[TBL] [Abstract][Full Text] [Related]
31. Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells.
Mahalingaiah PK; Ponnusamy L; Singh KP
Breast Cancer Res Treat; 2015 Aug; 153(1):41-56. PubMed ID: 26208486
[TBL] [Abstract][Full Text] [Related]
32. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
[TBL] [Abstract][Full Text] [Related]
33. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
35. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
36. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
Kala R; Tollefsbol TO
PLoS One; 2016; 11(5):e0155057. PubMed ID: 27159275
[TBL] [Abstract][Full Text] [Related]
37. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
Liu W; Ip MM; Podgorsak MB; Das GM
Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
[TBL] [Abstract][Full Text] [Related]
38. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M
Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
40. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts.
Bouclier C; Marsaud V; Bawa O; Nicolas V; Moine L; Opolon P; Renoir JM
Breast Cancer Res Treat; 2010 Jul; 122(1):145-58. PubMed ID: 19771505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
